Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agenus Inc AGEN

Healthcare Biotechnology
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its... see more

Recent & Breaking News (NDAQ:AGEN)

Agenus Eliminates Its $39 Million Senior Notes and Completes $10 Million of New Debt Financing

Globe Newswire April 16, 2013

Agenus' Brain Cancer Vaccine Results to be Presented at Plenary Session of the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting

Globe Newswire April 10, 2013

Agenus to Present at the ROTH Annual Conference

Troy Schwensen March 14, 2013

NW Bio Provides Guidance On Phase III Trial Enrollment Timing: Completion Expected To Be Faster Or More Efficient Than Relevant Comparison Trials

PR Newswire March 7, 2013

Agenus Reports Fourth Quarter and Year End 2012 Financial Results

Troy Schwensen February 28, 2013

Agenus' HerpV Phase 2 Study to Treat Genital Herpes Completes Enrollment

Troy Schwensen February 27, 2013

Agenus to Present at Cowen and Company Annual Healthcare Conference

Troy Schwensen February 26, 2013

Agenus to Report Fourth Quarter and Year End 2012 Financial Results on February 28, 2013; Conference Call to Follow

Troy Schwensen February 21, 2013

Agenus to Present at BIO CEO & Investor Conference

Troy Schwensen February 6, 2013

Agenus to Present at OneMedForum San Francisco 2013

Troy Schwensen January 2, 2013

The Real Story Behind PGNX, OSUR, NVGN and AGEN

Marketwired January 2, 2013